Japanese company Seiwa Corporation announced that they can now produce e-cigarette liquid containing high concentrations of CBD. Starting from September 1, 2022, the company will accept OEM and ODM orders for various electronic cigarette-related products.
Qindu, a company, has developed a method to produce a wide-spectrum high concentration CBD liquid using glycerin as a base. Existing e-cigarettes that use high concentration CBD liquids mainly rely on oil bases (such as terpenes and MCT), which are prone to crystallization and produce very little smoke. They are only suitable for use with limited e-cigarette devices. However, Qindu's research and development have enabled them to manufacture a glycerin-based liquid that can inhibit crystallization while maintaining a high concentration of CBD. This liquid is suitable for use in standard e-cigarettes.
Glycerol-based liquids can also be used with popular POD-type electronic cigarette devices and disposable devices compatible with the 510 thread.
We manufacture CBD liquid (in needle bottles of 10ml and 30ml), disposable e-cigarettes with 510 thread, and one-time disposable and exchangeable POD type VAPE devices (such as Mini xisha), all in our domestically-owned CBD factory with clean rooms. Additionally, we offer assistance with commercializing various CBD products, including oils, cosmetics, supplements, gummies, candies, beverages, and more. Even for small batches, we keep prices at a minimum. For inquiries, please feel free to contact us.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
